Lung Cancer Screening Study With Low-dose CT Scan and Blood Biomarker
Lung cancer is the number one cancer killer in the USA. Early stage lung cancer is asymptomatic. Most patients with lung cancer are usually symptomatic at diagnosis and already have advanced stage disease. Low dose CT screening (LDCT) for high risk individuals has recently been shown to decrease lung cancer mortality by 20%. However, 4 out of 5 lung cancer deaths are not prevented with LDCT screening alone.
Checked against the public recordLast updated Dec 31, 2020 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Screening
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- National Jewish Health
- Interventions being studied
- Radiation: CT scan & Early CDT Lung test; Other: CT scan & Early CDT Lung test
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Smokers or former smokers * At least 20 pack year history of smoking * Ages 50 - 75 Exclusion Criteria: * Had a CT scan of chest within last 24 months * History of any cancer within 10 yrs (except skin cancer or cervical cancer) * A serious illness that decreases life expectancy to less than 5 years * Any current use of Oxygen * Uncontrolled congestive heart failure or cardiac arrhythmia that would prevent surgery for a lung lesion * Severe COPD or dyspnea that would prevent lung surgery or stereotactic body radiotherapy
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- National Jewish HealthDenver, Colorado
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 31, 2020. Always confirm current availability with the study team.